
RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

09/830,111

Source:

PUT/09

Date Processed by STIC:

8/30/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

HH H

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 09/830,///
ATTN: NEW RULES CASES	S: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6Patentin 2.0	A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentln would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8 Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
12PatentIn-2.0 "bug"	Please do not use "Copy to Disk" function of Patentln version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/830,111

TIME: 11:37:14

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I830111.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: Kaneka Corporation

5 <120> TITLE OF INVENTION: Process for producing coenzyme Qlo

7 <130> FILE REFERENCE: T549/QX-GT2

8 <140> CURRENT APPLICATION NUMBER: US/09/830,111

8 <141> CURRENT FILING DATE: 2001-07-23

8 <150> PRIOR APPLICATION NUMBER: JP P1999-237561

9 <151> PRIOR FILING DATE: 1999-08-24

W--> 10 <160> NUMBER OF SEQ ID: 2

ERRORED SEQUENCES

W--> 11 <210> SEQ ID NO: 1

12 <211> LENGTH: 1653

13 <212> TYPE: DNA

14 <213> ORGANISM: Saioella complicata

W--> 15 <400> SEQUENCE: 1

E--> 17 20 ttttgtgggg tcgaaaagtc ggcacgggtg caggttcggc ttgagaccag taaaggctcg 60 19 gagattgagt tcaggacaaa gctttgatcc gtgaggtcta catcttcagc aaatcatttc 120

21 aaatccatat acc atg gcc tca cca gca ctg cgg ata cga agc atc agc 169

W--> 23 25 Met Ala Ser Pro Ala Leu Arg Ile Arg Ser Ile Ser

W--> 25 1 5 10

E--> 28 2

30 tot cga toa ato goo tot otg cga tog gtt aco ota aga aca goo tog 217

31 Ser Arg Ser Ile Ala Ser Leu Arg Ser Val Thr Leu Arg Thr Ala Ser

W--> 32 20 25

E--> 33 5

E--> 34 gca cct tca tta cga cta aga tgt acc cog acg ago cgg cca tcg agt 265

35 Ala Pro Ser Leu Arg Leu Arg Cys Thr Pro Thr Ser Arg Pro Ser Ser

W--> 36 30 35 40

E--> 38 10 tca tgg get get get gtg tct tcg gcg tcg aga ctg gtt gag cct gat 313

W--> 39 Ser Trp Ala Ala Ala Val Ser Ser Ala Ser Arg Leu Val Glu Pro Asp

W--> 40 45 50 55 6

42 ccg aat caa cct ctc atc aat ccg ctc aac ttg gtc ggt ccc gag atg 361

W--> 43 15 Pro Asn Gln Pro Leu Ile Asn Pro Leu Asn Leu Val Gly Pro Glu Met

W--> 44 65 70 75

45 tca aat ctt aca tcc aac atc cga tct ctc ctc ggt tca gga cac cct 409

46 Ser Asn Leu Thr Ser Asn Ile Arg Ser Leu Leu Gly Ser Gly His Pro

I--> 47 20 80 85 90

E--> 49 tct ctc gac act gtc get aaa tac tat gtt cag tct gag gga aag cat 457

50 Ser Leu Asp Thr Val Ala Lys Tyr Tyr Val Gln Ser Glu Gly Lys His

W--> 51 95 100 105

E--> 52 25

E--> 53 att cgt cog ctc atg gta ctg ctg atg get cag gcg acg gag gtt gcg 505

E--> 57 3

59 Ile Arg Pro Leu Met Val Leu Leu Met Ala Gln Ala Thr Glu Val Ala

W--> 60 110 115 120

see following pages for explanation-


ever

Pliese

feguera

for valid

Sequence listing <110> Kaneka Corporation <120> Process for producing coenzyme Qlo <130> T549/QX-GT2 <150> JP P1999-237561 <151> 1999-08-24 <160> 2 <210> 1 <211> 1653 <212> DNA <213> Saioella complicata <400> 1 ttttgtgggg tcgaaaagtc ggcacgggtg caggttcggc ttgagaccag taaaggctcg 60 gagattgagt tcaggacaaa gctttgatcc gtgaggtcta catcttcagc aaatcatttc 120 aaatccatat acc atg gcc tca cca gca ctg cgg ata cga agc atc agc (Met Ala Ser Pro Ala Leu Arg Ile Arg Ser Ile Ser musabjred has, - sel den 3 amino aude MUST be on Ever human directly under tct cga tca atc gcc tct ctg cga tcg gtt acc cta aga aca gcc tcg 217 Ser Arg Ser Ile Ala Ser Leu Arg Ser Val Thr Leu Arg Thr Ala Ser invalid nucleic acid designator misaligned gca cet tea tta ega eta aga tgt ace cog acg ago egg cea teg agt 265 Ala Pro Ser Leu Arg Leu Arg Cys Thr Pro Thr Ser Arg Pro Ser Ser 40 tca tgg get get gtg tct tcg gcg tcg aga ctg gtt gag cct gat Ser Trp Ala Ala Ala Val Ser Ser Ala Ser Arg Leu Val Glu Pro Asp tet teg geg teg aga etg gtt gag eet gat 313 45 55 aat caa cct ctc atc aat ccg ctc aac ttg gtc ggt ccc gag atg 361 Pro Asn Gln Pro Leu Ile Asn Pro Leu Asn Leu Val Gly Pro Glu Met tca, aat ctt aca tcc aac atc cga tct ctc ctc ggt tca gga cac cct 409 Ser Asn Leu Thr Ser Asn Ile Arg - Ser Leu Leu Gly Ser Gly His Pro 20 90 tet ete gae act gte get aaa tac tat gtt eag tet gag gga aag eat 457 Ser Leu Asp Thr Val Ala Lys Tyr Tyr Val Gln Ser Glu Gly Lys His att cgt cog ctc atg gta ctg ctg atg get çag gcg acg gag gtt gcg 505



(5)	
Ala Tyr Ala Tyr Gly Arg Asn Leu Gly Leu Ala Phe Gln Ile Val Asp (320 325 330) musalique	
gac atg ctc gac tac acc gtc tcc get acc gac ctc ggt aag ccc gcc 1177 (5) Asp Met Leu Asp Tyr Thr Val Ser Ala Thr Asp Leu Gly Lys Pro Ala inove 335 340 345	
ggt gca gac ctc cag ctc ggt ctc gcc acc gcg ccg gcc ctc ttc gca 1225 Gly Ala Asp Leu Gln Leu Gly Leu Ala Thr Ala Pro Ala Leu Phe Ala Line lower-cons letter (0) (350 355 360	
tgg aag cac cac gcc gag ctc ggt ccc atg atc aag cgc aag ttc tct Trp Lys His His Ala Glu Leu Gly Pro Met Ile Lys Arg Lys Phe Ser 365 370 375 380	1273
gac cca gga gac gtc gag cgt gca cgc gag ttg gtc gag aaa agt gat 1321 Asp Pro Gly Asp Val Glu Arg Ala Arg Glu Leu Val Glu Lys Ser Asp	
gga ttg gag aag acg aga gcc ttg gcg gag gag tat gcc cag aag gcg Gly Leu Glu Lys Thr Arg Ala Leu Ala Glu Glu Tyr Ala Gln Lys Ala 400 405 410	1369
ttg gat gca att cgg acg ttc ccg gag agt cog gca cgg aag get ttg 1417	
415 420 425	
gag cag ttg acg gac aag gtg ttg act agg tca aga taggaattcgagct I Glu Gln Leu Thr Asp Lys Val Leu Thr Arg Ser Arg	sent a space after
gag cag ttg acg gac aag gtg ttg act agg tca aga taggaattcgagct 1 Glu Gln Leu Thr Asp Lys Val Leu Thr Arg Ser Arg 430 435 440	1467 lock group of
eggtaceegg ggateeteta gagtegaeet geaggeatge aagettgget gttttggegg 1527	7 70 600
atgagagaag attttcagcc tgatacagat taaatcagaa cgcagaagcg gtctgataaa 1587	7
acagaatttg cetggeggea gtagegeggt ggteecacet gaceceatge egaacteag	ga 1647
7/653 agtgaa 7/653	sel dem I on Ever Summary
15 <210> 2 	on Ever
211> 440 <212> PRT	Sumay
<213> Saioella complicata	fleet
(20) <400> 2 Met Ala Ser Pro Ala Leu Arg Ile Arg Ser Ile Ser Ser Arg Ser	

2	1	·				5							10		n	rse	Ü	reo
15 11e	Ala	Ser	Leu	Arg		Val 20	Thr	Leu	Arg	Thr	Ala	Ser	Ala- 25	Pro	<i>></i>		0	, ,
30 -	Se	er Le	eu Ai	rg L			ys Tì	nr P: 35	ro Ti	nr Se	er Ai	rg Pı	co Se	er Se	er S 40	Ser	-	
(43)							 -											
Trp	Ala	Ala	Ala	Val	Ser	Ser	Ala	Ser	Arg	Leu	Val	Glu	Pro	Asp	.5	_		
						50				55	5				(50	>	
Pro	Asn	Gln	Pro	Leu	Ile	Asn	Pro	Leu	Asn	Leu	Val	Gly	Pro	Glu				
	/					65					70					75	>	
(5)	Me	et Se	er As	sn L	eu Tl	hr Se	er As	sn I	le A	rg Se	er Le	eu Le	eu Gl	Ly Se	er (Sly		
Ç						80					35					90	>	
His	Pro	Ser	Leu	Asp	Thr	Val	Ala	Lys	Tyr	Tyr	Val	Gln	Ser	Glu				
						95				10	00	مر				105	>	
Gly	Lys	His	Ile	Arg	Pro	Leu	Met	Val	Leu	Leu	Met	Ala	Gln	Ala				
(10)						110				11	15					120	>	
Thr	Glu	Val	Ala	Pro	Lys	Val	Gln	Gly	Trp	Glu	Lys	Val	Val	Glu				
						125					130					135	•	
Val	Pro	Val	Asn	Glu	Gly	Leu	Ala	Pro	Pro	Glu	Val	Leu	Asn	Asp				
~ <i>[</i>	((140				14	15					158		
(15)	L	ys As	sn Pi	ro A	sp M	et Me	et As	sn Me	et A	rg Se	er Gl	Ly Pi	co Le	eu Th	nr I	ys		
						(1	55]	160				1	165		
Asp	Gly	Glu	Ile	Glu	Gly	Gln	Thr	Ser	Asn	Ile	Leu	Ala	Ser	Gln				
						170					175					180	>	
Arg	Arg	Leu	Ala	Glu	Ile	Thr	Glu	Met	Ile	His	Ala	Ala	Ser	Leu				
$(2\hat{0})$						185					190					195	>	
Leu	His	Asp	Asp	Val	Ile	Asp	Ala	Ser	Glu	Thr	Arg	Arg	Asn	Ala				
						200				2	205					210	\supset	
Pro	Ser	Gly	Asn	Gln	Ala	Phe	Gly	Asn	Lys	Met	Ala	Ile	Leu	Ala				
				•		215				2	220					225		>

(25)	Glv Asp Phe	Ten Len Glv Arc	, Ala Ser Val Ala Leu Ala	a Arg Leu
	01, 1.0, 11.0	230	235	240
	Arg Asn Pro	Glu Val Ile Glu	Leu Leu Ala Thr Val Ile 250	Ala Asn 255
		=	Gin Leu Lys Asn Thr Val	· · · · · · · · · · · · · · · ·
(5)	260 Ala Ile Glu		265 Gin Glu Thr Phe Asp Tyr	270 Tvr Leu
		275	280	285
	Gln Lys Thr		Ala Ser Leu Ile Ala Lys	
١	Arg Ala Ser	290 Ala Leu Leu Gly	295 / G <u>ly Ala Thr Pro Glu Va</u> l	Ala Asp
\bigcap	-			
10	Ala Tur Ala T	ur Gly Arg Asn I	310 Leu Gly Leu Ala Phe Gin I	315
AIG	-	20	00-	330 extra Spaces
	Val Asp Asp	Met Leu Asp Tyr		Sp Leu Gly
(15	Lvs Pro Ala	Glv Ala Asp Leu	340 I Gin Leu Gly Leu Ala Thr	Ala Pro
\cup	_,,	<u> </u>	355	360
,	Ala Leu Phe	Ala Trp Lys His 365	His Ala Glu & Leu Gly 370 duta & Tra	Pro Met Ile Spaces 375
_ }	Lvs Arg Lvs		Gly Asp Val C Glu Arg	•
20		380	385	390
\bigcup .	Leu Val Glu	Lys Ser Asp Gly	Leu Glu Lys C Thr Arg	
	Glu Glu Tyr	Ala Gln Lys Ala		Thr Phe Pro
)	-	ِ 410	415	420
$\binom{25}{25}$	Glu Ser Pro	Ala Arg Lys Ala	Leu Glu Gln Leu Thr Asp	Tue Val
(2)	GIU SEI FIO	(425)	430	435 —
	dastes	not permits	ref	
Leu	Thr-Arg- Ser	•		
	la ralid	440	•	